# Doxorubicin With or Without DT-7012 in Advanced Soft Tissue Sarcoma

Source: https://onco.cc/trials/nct07802652/  
OnCo record `nct07802652` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of DT-7012 run by Gustave Roussy, Cancer Campus, Grand Paris, not yet recruiting.

## Summary

Doxorubicin With or Without DT-7012 in Advanced Soft Tissue Sarcoma is a phase 2 interventional study registered as NCT07802652 by Gustave Roussy, Cancer Campus, Grand Paris, with 80 participants planned, started 2027-02-01. Conditions recorded: Undifferentiated Pleomorphic Sarcoma (UPS) and Dedifferentiated Liposarcoma (DDLPS). Interventions recorded: DT-7012 and Doxorubicin.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07802652
- Phase: 2
- Setting: A Randomized Phase II Study of Doxorubicin With or Without DT-7012 in Advanced Soft Tissue Sarcoma
- Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
- Enrolled: 80

## Sources

- ClinicalTrials.gov NCT07802652: https://clinicaltrials.gov/study/NCT07802652

## Connected records

- cancers: [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/), [Undifferentiated pleomorphic sarcoma (UPS)](https://onco.cc/cancers/undifferentiated-pleomorphic-sarcoma/)
- drugs: [DT-7012](https://onco.cc/drugs/dt-7012/)
- companies: [Kainova Therapeutics](https://onco.cc/companies/domain-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct07802652.json